IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

ZAGAMI, PAOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.188
AS - Asia 575
NA - Nord America 534
SA - Sud America 66
OC - Oceania 12
AF - Africa 9
Continente sconosciuto - Info sul continente non disponibili 1
Totale 3.385
Salva come PNG Salva come JPEG
Nazione #
DE - Germania 1.482
US - Stati Uniti d'America 515
IT - Italia 218
CN - Cina 198
SE - Svezia 168
SG - Singapore 147
NL - Olanda 80
GB - Regno Unito 65
IN - India 64
HK - Hong Kong 60
RU - Federazione Russa 55
BR - Brasile 49
IE - Irlanda 34
FI - Finlandia 25
FR - Francia 21
ID - Indonesia 21
KR - Corea 19
VN - Vietnam 18
CA - Canada 17
JP - Giappone 10
AR - Argentina 9
AT - Austria 8
AU - Australia 8
AM - Armenia 6
CZ - Repubblica Ceca 6
PH - Filippine 5
TW - Taiwan 5
BE - Belgio 4
NO - Norvegia 4
NZ - Nuova Zelanda 4
UA - Ucraina 4
EG - Egitto 3
TR - Turchia 3
UZ - Uzbekistan 3
BD - Bangladesh 2
CH - Svizzera 2
CL - Cile 2
CO - Colombia 2
EC - Ecuador 2
IR - Iran 2
LV - Lettonia 2
MA - Marocco 2
MO - Macao, regione amministrativa speciale della Cina 2
MX - Messico 2
PK - Pakistan 2
PL - Polonia 2
PS - Palestinian Territory 2
TH - Thailandia 2
ZA - Sudafrica 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BO - Bolivia 1
DK - Danimarca 1
EE - Estonia 1
ES - Italia 1
GE - Georgia 1
HU - Ungheria 1
IS - Islanda 1
JO - Giordania 1
KE - Kenya 1
KW - Kuwait 1
PE - Perù 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 3.385
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 1.404
Chandler 87
Milan 87
Singapore 85
Santa Clara 54
Southend 52
Hong Kong 43
Council Bluffs 36
Dublin 34
Ashburn 28
Princeton 24
Hyderabad 20
Düsseldorf 19
Jakarta 19
Helsinki 16
Munich 14
Seoul 14
Cangzhou 13
Shanghai 13
Toronto 13
Los Angeles 12
Beijing 11
Bengaluru 11
Berlin 11
Nuremberg 9
Tokyo 9
Des Moines 8
Fairfield 8
Fuzhou 8
Naples 8
Seattle 8
Amsterdam 7
Chennai 7
Oklahoma City 7
Salt Lake City 7
Boston 6
Chicago 6
Phoenix 6
Buenos Aires 5
Cambridge 5
Dong Ket 5
Fisciano 5
Guangzhou 5
Lappeenranta 5
New York 5
Paris 5
Vienna 5
Wuhan 5
Yerevan 5
Antioch 4
Auckland 4
Brussels 4
Changsha 4
Lauterbourg 4
Rome 4
Turku 4
Wilmington 4
Ann Arbor 3
Arezzo 3
Boardman 3
Brisbane 3
Brno 3
Cary 3
Groningen 3
Ho Chi Minh City 3
Moscow 3
Oslo 3
San Antonio 3
Silver Spring 3
Taipei 3
Tashkent 3
The Dalles 3
Turin 3
Uxbridge 3
Albino 2
Antegnate 2
Bergamo 2
Betim 2
Brasília 2
Brembate di Sopra 2
Bresso 2
Buffalo 2
Bühl 2
Cairo 2
Cartersville 2
Chingford 2
Ciserano 2
Cosenza 2
Eaubonne 2
Elk Grove Village 2
Florence 2
Gainesville 2
Grafing 2
Guayaquil 2
Houston 2
Istanbul 2
Jiaxing 2
Kelowna 2
Livorno 2
Lodi 2
Totale 2.414
Salva come PNG Salva come JPEG
Nome #
Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis 161
Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure 157
Pretreatment Blood Parameters Predict Efficacy from Immunotherapy Agents in Early Phase Clinical Trials 156
Sex-based dimorphism of anticancer immune response and molecular mechanisms of immune evasion 150
Systemic Treatment of Ductal Carcinoma In Situ of the Breast 144
Assessing predictors of tamoxifen nonadherence in patients with early breast cancer 142
Pathological and clinical features of enteric adenocarcinoma of the thymus. A pooled analysis of cases from a reference center and systematic review of the literature 141
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents 134
Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2 132
What therapies are on the horizon for HER2 positive breast cancer? 131
Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials 130
Metaplastic breast cancer: an all-round multidisciplinary consensus 123
First line treatment of BRAF mutated advanced melanoma: Does one size fit all? 123
Evolution of low HER2 expression between early and advanced-stage breast cancer 123
Triple negative breast cancer: Pitfalls and progress 122
Tumor-infiltrating lymphocytes (TILs) in paired samples from patients with phenotypic switch from early luminal-like to metastatic triple-negative breast cancer 120
Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial 113
Antibody-drug conjugates in breast cancer : the chemotherapy of the future? 106
Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation? 97
Characterization of low HER2 expressions in de-novo metastatic breast cancer 94
The rare entity of gastrointestinal leiomyosarcomas: An Italian multicenter retrospective study in high‐volume referral centers 91
Baseline tumor size as prognostic index in patients with cancer receiving experimental targeted agents 88
Management of Patients with Cardiac Toxicity: The Point of View of the Oncologist 82
Fed or fasted state for oral therapies in breast cancer treatment? A comprehensive review of clinical practice recommendations 78
Invasive lobular breast cancer: Focus on prevention, genetics, diagnosis, and treatment 73
Management of Cardiac Toxicity Induced by Chemotherapy 72
Cardiotoxicity of Agents Used in Patients With Breast Cancer 66
HER2-positive breast cancer: cotargeting to overcome treatment resistance 62
Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases 57
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors 44
Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer 41
Immunotherapy in the treatment landscape of hormone receptor-positive (HR+) early breast cancer: is new data clinical practice changing? 32
UNDERSTANDING METASTASIS MIXED - TREATMENT RESPONSES THROUGH GENOMIC ANALYSES. 23
Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study 22
Endocrine therapy for early breast cancer in the era of oral selective estrogen receptor degraders: challenges and future perspectives 20
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors 15
Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations 15
The rare entity of bilateral and unilateral neuroendocrine metastases to the breast: A case series and literature review 13
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer 12
PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative 11
null 6
Real-World Clinical Outcomes With Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer 4
EGFR-TKI plus anti-angiogenic drugs in EGFR-mutated non–small cell lung cancer: A meta-analysis of randomized clinical trials 4
null 3
Pembrolizumab and oral metronomic cyclophosphamide in patients with chest wall breast cancer (PERICLES): an immune-biomarker analysis of tumor infiltrating lymphocytes (TILs) and programmed cell death ligand protein 1 (PD-L1) 3
null 3
Understanding metastasis mixed-treatment responses through genomic analyses 1
Oral selective estrogen receptor degraders for breast cancer treatment: focus on pharmacological differences 1
Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study 1
Molecular tumor board in patients with metastatic breast cancer 1
Abstract HER2-02: HER2-02 HER2-Low Status is Associated with Worse Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Patients Treated With First-Line Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy 1
Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment 1
Spectral CT for non-invasive evaluation of bladder cancer grade 1
Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC) 1
Different Response to Immunotherapy According to Melanoma Histologic Subtype 1
Effect of age on safety and efficacy of novel cancer drugs investigated in early-phase clinical trials 1
An update on promising and emerging protein kinase B/AKT inhibitors for breast cancer 1
Multimodal histopathologic models stratify hormone receptor-positive early breast cancer 1
Totale 3.551
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.208
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.208
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202179 0 0 0 0 0 2 0 0 20 14 21 22
2021/2022275 8 16 10 40 24 23 11 20 45 9 29 40
2022/2023325 53 45 35 18 22 51 3 20 38 5 23 12
2023/20241.380 21 34 40 49 103 74 197 162 78 173 227 222
2024/20251.477 191 187 170 160 101 71 51 164 114 193 75 0
Totale 3.551